TESORX LICENSES TESTOSTERONE REPLACEMENT THERAPY TECHNOLOGY
Novel testosterone oral drug delivery technology licensed by TesoRx
(San Francisco, CA) July 30, 2010 – TesoRx Pharma, LLC., a California-based pharmaceutical company, announced today that it has secured the licensing rights to a novel formulation of testosterone replacement therapy.
The company plans on developing the formulation as TSX-002 and obtain FDA approval for commercial exploitation by as early as 2013. TR Thirucote, the company’s CEO, said “This is an exciting milestone for TesoRx. TSX-002 will address the $1Bn testosterone replacement therapy market and is an ideal example of the type of opportunities that the company will be targeting in the future”. On current treatments available for testosterone deficiency he said “Injectible treatments are uncomfortable for patients while topical treatments can unintentionally be transferred between individuals and have a black box warning for safety reasons. No oral formulations currently exist within the USA. We believe that TSX-002 will fill this void in the market and represent a significant advance in the treatment of testosterone deficiency.”
As part of the licensing transaction, Dr. Guru Betageri will be joining the company as Chief Scientific Advisor. Dr. Betageri’s area of expertise is in solid dosage forms and he has been instrumental in the formulation and development of several products in the market.
TesoRx Pharma LLC is focused on rapidly developing and commercializing pharmaceutical products in rare and specialty markets with limited treatment options and high unmet need. Its growing pipeline includes assets in urology, oncology and rare diseases that have been formulated with TesoRx’s proprietary proliposomal delivery technology. The company was founded in 2010 through a collaboration with Western University of Health Sciences that includes joint R&D efforts at the TesoRx Centre of Excellence in Pomona, California. More information at www.tesorx.com
More information at www.tesorx.com
Binay Curtis, Galaxy Six Strategies Public Relations: Binay@galaxysix.com